Conjunctival Neoplasms Clinical Trial
Official title:
Effect of Ranibizumab on Malignant Conjunctival Neoplasia
The purpose of this study is to test the safety and tolerability of subconjunctival
injection of ranibizumab in the treatment of malignant conjunctival neoplasia using the
incidence and severity of adverse events.
Our secondary objective is to assess the efficacy of ranibizumab treatment on malignant
conjunctival neoplasia by evaluating tumor destruction or reduction as documented by
slit-lamp photography and ultrasonographic imaging and the regression of blood vessels.
Ranibizumab is a recently approved vascular endothelial growth factor (VEGF) inhibitor shown
to be effective in treating exudative macular degeneration. Its analog, Avastin has also
been employed to treat macular edema, proliferative diabetic retinopathy and wet age related
macular degeneration. Ranibizumab binds to and inhibits vascular endothelial growth factor A
(VEGF-A), which has been shown to cause neovascularization and leakage in models of ocular
angiogenesis. Binding to VEGF-A prevents ranibizumab's interaction with VEGFR-1 and -2
receptors on the surface of endothelial cells, thereby reducing proliferation, vascular
leakage, and angiogenesis.
Given that conjunctival tumors require the formation of new blood vessels to supply the
proliferating cells, we propose a study to evaluate the effect of subconjunctival
ranibizumab as a primary intervention in patients with conjunctival tumors.
;
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03515954 -
AS-OCT Guided Treatment of Diffuse CSCC
|
||
| Recruiting |
NCT05645341 -
Artificial Intelligence-assisted Screening of Malignant Pigmented Tumors on the Ocular Surface
|